ドライアイ（DED）- 市場洞察、疫学、市場予測 2028年
Dry Eye Disease (DED) - Market Insights, Epidemiology and Market Forecast-2028
|発行||DelveInsight Business Research LLP||商品コード||602051|
|出版日||ページ情報||英文 156 Pages
|ドライアイ（DED）- 市場洞察、疫学、市場予測 2028年 Dry Eye Disease (DED) - Market Insights, Epidemiology and Market Forecast-2028|
|出版日: 2019年08月01日||ページ情報: 英文 156 Pages||
DelveInsight's 'Dry Eye Disease (DED) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of DED in EU5 (Germany, Spain, Italy, France and United Kingdom).
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Dry Eye Disease (DED) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017-2028
The DelveInsight Dry Eye Disease (DED) market report gives the thorough understanding of the Dry Eye Disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Dry Eye Disease in Europe.
The Dry Eye Disease (DED) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 5 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, diagnosed cases, gender-specific prevalent cases, severity-specific prevalent cases, type-specific prevalent cases and age-specific prevalent cases) scenario of Dry Eye Disease (DED) in the 7MM covering EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017-2028.
According to DelveInsight, the total number of prevalent cases of Dry Eye Disease (DED) in 7 MM was found to be 11,939,169, in the year 2017.
This segment of the Dry Eye Disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are many over the counter therapies such as "artificial tears", ocular surface lubricants that have been used since a very long time to treat DED. These therapies have been included in DelveInsight's forecast model since it focuses both on the prescription therapies as well as OTC products such as Hyaluronic acid, Polyvinyl alcohol, Sodium chloride, Hypromellose, Poly(1-vinyl-2-pyrrolidon), Povidone, Carboxymethylcellulose, Ketorolac tromethamine, Hypromellose and many others that are being used to treat DED. Some of the major products belonging to this category are Novatears/Evotears (Novaliq/Ursapharm), Genteal/Systane/Tears Naturale (Alcon/Novartis), Refresh/Optive (Allergan), Soothe (Bausch & Lomb/Valeant, Visu XL/Xailin Hydrate/Xailin Gel (Visufarma) and many others. Detailed chapter for upcoming therapies like Visomitin, RGN-259 and many others have been covered in the report.
The Dry Eye Disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Dry Eye Disease in 5MM was found to be USD 602.62 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.